GNFT (GNFT) News
Track canonical SquawkNews coverage tagged to GNFT, GNFT. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
GNFT NIS2+ set to transform MASH diagnostics and patient monitoring
TradingView News says GNFT’s NIS2+ is positioned as a scalable, non-invasive solution for MASH diagnostics, validated by independent studies, aimed at enabling patient identification and monitoring.
EQUITY | Sep 09, 2026, 05:03 PM UTC
L
GNFT targets scalable non-invasive MASH diagnosis, ~$1.5B market by 2033
Genfit says a scalable, non-invasive diagnostic for at-risk MASH could unlock an annual lab market of about $1.5B by 2033. It highlights moving from LDT to IVD and expanding payer coverage.
EQUITY | Sep 09, 2026, 03:56 PM UTC
L
GNFT scalable MASH diagnostics projections point to $1.5B+ U.S. sales by 2033
A hepatology expert said there is urgent need for scalable, non-invasive MASH diagnostics. Projections cited U.S. peak sales that could exceed $1.5 billion by 2033, helped by new therapies and adoption.
EQUITY | Sep 09, 2026, 03:47 PM UTC
L
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
Lille (France), Cambridge (Massachusetts, United States), September 9, 2026 - GENFIT Euronext:GNFT, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases,
EQUITY | Sep 09, 2026, 05:37 AM UTC
L
GNFT: Robust pipeline and partnerships drive growth in rare liver diseases and diagnostics
GNFT: Robust pipeline and partnerships drive growth in rare liver diseases and diagnostics
EQUITY | Sep 01, 2026, 07:41 AM UTC